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Table 1 Multiple linear regression analysis: independent predictors of
baPWV in CKD ND.
Variables Not adjusted Adjusted
b coefficient p b coefficient p
Age (years) 0.36 <0.001
DBP (mmHg) 0.31 <0.001
BMI (kg/m2) 0.18 <0.001
Serum25(OH)D3 (ng/mL) 0.36 <0.001 0.18 <0.001
Adjusted R2 0.13 0.45
baPWV Z brachial-ankle pulse wave velocity; CKD ND Z non-dialysis-
dependent CKD; BMIZ body mass index; DBPZ diastolic blood pressure.
In this model, gender, serum creatinine, hemoglobin, albumin, calcium,
phosphate, iPTH, eGFR, LDL-C, TC, DM, and HTN were also included as
S114 Chronic Kidney Diseasecovariates, but they were not independently associated with baPWV.http://dx.doi.org/10.1016/j.hkjn.2015.09.167
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Relationship Between Calcium Phosphate Metabolism and Parathyroid
Hormone and Chronic Kidney Disease
X. Z. Zheng
The 211 Hospital of PLA, Harbin, Heilongjiang Province, China
Objective: To understand the status of calcium and phosphorus metabolism
and parathyroid hormone (iPTH) level in patients with chronic kidney disease
(ESRD), and to analyze the significance of calcium and phosphorus meta-
bolism and parathyroid hormone in chronic kidney disease.
Methods: Collected 100 cases of patients with chronic kidney disease, which
were divided into 3 groups according to the value of the glomerular filtration
rate (GFR): group 1 (30 cases, GFR 89e60 ml/min), group 2 (35 cases, GFR
59e30 ml/min) and group 3 (35 cases, GFR < 30 ml/min), while set up
GFR > 90 ml/min as the control group. Calcium, phosphorus and parathyroid
hormone (iPTH) were measured.
Results: In the control group, calcium, phosphorus and parathyroid hor-
mone (iPTH) levels showed no obvious abnormalities. In group 1, 23.1%
of patients had serum phosphorus increased, only 2 people had slightly
parathyroid hormone increased, while serum calcium level had no obvious
abnormalities. In group 2, 43.2% of patients had significantly serum phos-
phate elevated, 5 persons had parathyroid hormone mildly elevated.
Serum calcium levels have decreased; 72.1% of patients in group 3 had
significantly serum phosphate increased, and 47%of the patients had para-
thyroid hormone increased. Serum calcium levels gradually decreased
together with GFR declined.
Conclusion: When GFR decline to 89e60 ml/min, serum phosphorus increase
and parathyroid hyperfunction show up. When the GFR < 60 ml/min, the in-
crease of blood phosphorus and parathyroid hormone are accelerated. When
GFR < 30 ml/min the level of serum phosphorus, parathyroid hormone and
serum calcium appear unusually severe, which means in phase 2 and 3
ESRD high phosphorus acidemia appears first, and in phase 4 and 5 ESRD
serum calcium level abnormal, and nearly 50% of the patients had secondary
hyperparathyroidism. Calcium phosphorus metabolism and parathyroid hor-
mone (iPTH) levels were positively correlated with the severity of chronic
kidney disease.http://dx.doi.org/10.1016/j.hkjn.2015.09.169
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Observational Study of the Efficacy and Safety of Bisoprolol Fumarate in
Chronic Kidney Disease Patients with Hypertension Uncontrolled with
Metoprolol or Arotinolol
Yue Rongzheng, Tao Ye
Sichuan University, Chengdu, China
Objective: To study retrospectively the efficacy and safety of highly selec-
tive b1-blocker bisoprolol fumarate in chronic kidney disease patients with
hypertension uncontrolled with metoprolol or arotinolol.
Methods: 97 hypertension patients with stage 3e5 chronic kidney disease
who visited Renal Department of Internal Medicine of West China Hospitalof Sichuan University between January 2013 and September 2014 were
included. Every patient was prescribed metoprolol or arotinolol for more
than 7 days before inclusion with inadequate blood pressure control. Meto-
prolol or arotinolol was replaced with similar dosage of bisoprolol fumarate
with other combination therapy unchanged. The variation of clinic systolic
blood pressure, diastolic blood pressure, mean arterial pressure, heart
rate, liver function, kidney function, serum glucose, serum lipids and
adverse events were reevaluated at least 14 days later.
Results: Systolic blood pressure decreased 19.77  12.64 mmHg, diastolic
blood pressure decreased 14.87  8.42 mmHg, mean arterial pressure
decreased 16.41  8.92 mmHgand heart rate decreased 5.86  1.73
beats/min,all treating indications statistically significantly decreased
(P < 0.0001), at least 14 days after switching to similar dosage of bisoprolol
fumarate. No statistically significant difference was observed in renal func-
tion, liver function, uric acid, serum glucose and serum lipids before and af-
ter switching.
Conclusion: Bisoprolol fumarate associated significantly with reduced blood
pressure and heart rate in hypertension patients with stage 3e5 chronic kid-
ney disease who were uncontrolled with similar dosage of metoprolol or aro-
tinolol treated for more than 7 days, and also associated with safety and
good tolerance in this population.http://dx.doi.org/10.1016/j.hkjn.2015.09.170
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Effect of Renal Anemia on Left Ventricular Hypertrophy in Patients with
Non-dialysis Chronic Kidney Disease
Ying Jun, Wang Zheng-tong, Huang Jian
Jinhua Municipal Central Hospital, Jinhua, Zhejiang, China
Objective: To investigate the changes of left ventricular structure in non-
dialysis chronic kidney disease (CKD) patients with different degrees of
anemia.
Methods: To retrospectively analyze clinical data (including gender, age,
blood routine, renal function, electrolyte and cardiac color ultrasound) of
152 patients with non-dialysis CKD2e5 diagnosed in our hospital between
January and December 2014.
Results: There were no significant differences (P > 0.05) in patients’ base-
line clinical data (including age, gender, primary disease, nutritional status,
the incidence rate of hypertension, the use of various antihypertensive
drugs). The total prevalence of left ventricular hypertrophy (LVH) was up
to 61.28%. Meanwhile, with the decline in renal function, left ventricular
end-diastolic diameter and thickness of myocardium (left ventricular poste-
rior wall thickness and interventricular septal thickness) kept increasing
(P < 0.05). The same happened to the left ventricular mass and mass index
(P < 0.005) which also increased with the development of anemia. It is worth
mentioning that the prevalence of LVH in women is higher than that of men
(68.9% vs. 32.4%, P Z 0.000). Relatively increasing thickness of ventricular
wall appeared in 72.03% of the patients. Among them, 45.38% of the patients
presented with concentric hypertrophy of cardiac muscle, and 12.61% of the
patients presented with eccentric hypertrophy of cardiac muscle.
Conclusion: LVH widely exists in patients with chronic kidney disease, and
anemia is an important factor of LVH in CRF patients before dialysis. Then
early treatment of anemia can reverse LVH in some patients.http://dx.doi.org/10.1016/j.hkjn.2015.09.171
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Perioperative Use of Recombinant Human Erythropoietin for Kidney
Transplantation: A Meta-analysis
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Division of Nephrology, Kidney Research Institute, West China Hospital of
Sichuan University, Chengdu, China
Objective: Protective effect of rHuEPO for allograft in kidney transplan-
tation has not been established. Therefore, we conducted a meta-anal-
ysis to evaluate the potential influence of rHuEPO on transplanted
kidney.
Methods: To identify relevant studies, we searched electronic databases
(PubMed, Medline, EMBASE, Ovid, the Cochrane Library, and major
nephrology journals) on 28 January 2015. We used a fixed effects model to
calculate all summary measures of treatment effects.
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Fig. 2 Forest plot with 95% confidence interval in DGF (A), SGF (B), PNF (C), and graft loss (D) in patients treated with rHuEPO compared with controls.
Chronic Kidney Disease S115Results: Six studies with a total of 356 patients met the inclusion criteria.
rHuEPO, compared with placebo, had no statistically significant effect on
delayed graft function (DGF) [risk ratio (RR)Z 0.89; 95% confidence interval
(CI), 0.73e1.07; PZ 0.22] and slow graft function (SGF) (RRZ 0.93; 95% CI,
0.60e1.43; P Z 0.73). The rHuEPO and control groups did not differ in
thromboembolic events, mortality, acute rejection, and blood transfusion.
However, significant difference was demonstrated in long-time eGFR, which
indicated that rHuEPO may be favorable to allograft function in the long
term.Conclusion: Available evidence from our meta-analysis suggests that rHuEPO
has a certain nephroprotective effect in patients with kidney transplantation
without increasing the susceptibility to adverse events.http://dx.doi.org/10.1016/j.hkjn.2015.09.172
